Shlomo Noy
Director/Miembro de la Junta en Innovalve Bio Medical Ltd. .
Perfil
Shlomo Noy is currently a Director at Innovalve Bio Medical Ltd.
where he started in 2018.
He previously worked as a Director at Medx Xelerator LP.
Cargos activos de Shlomo Noy
Empresas | Cargo | Inicio |
---|---|---|
Innovalve Bio Medical Ltd.
Innovalve Bio Medical Ltd. Medical SpecialtiesHealth Technology Innovalve Bio Medical Ltd. is an Israeli medical device company that specializes in developing catheter-delivered heart valve therapies. Innovalve Bio Medical was founded in 2017 by Boris Orlov and Ehud Raanani, and is currently based in Ramat Gan, IL. The company aims to address the prevalent and progressive disease of Mitral Regurgitation (MR), which affects nearly 1 in 10 people aged 75 and older. MR is a progressive disease that can lead to advanced stages of MR, heart failure, and other complications. Eyal Baror has been the CEO of the company since 2020. | Director/Miembro de la Junta | 09/08/2018 |
Antiguos cargos conocidos de Shlomo Noy.
Empresas | Cargo | Fin |
---|---|---|
Medx Xelerator LP
Medx Xelerator LP Medical SpecialtiesHealth Technology Medx Xelerator LP provides medical devices incubator. The company is headquartered in Or Yehuda, Israel. | Director/Miembro de la Junta | - |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Medx Xelerator LP
Medx Xelerator LP Medical SpecialtiesHealth Technology Medx Xelerator LP provides medical devices incubator. The company is headquartered in Or Yehuda, Israel. | Health Technology |
Innovalve Bio Medical Ltd.
Innovalve Bio Medical Ltd. Medical SpecialtiesHealth Technology Innovalve Bio Medical Ltd. is an Israeli medical device company that specializes in developing catheter-delivered heart valve therapies. Innovalve Bio Medical was founded in 2017 by Boris Orlov and Ehud Raanani, and is currently based in Ramat Gan, IL. The company aims to address the prevalent and progressive disease of Mitral Regurgitation (MR), which affects nearly 1 in 10 people aged 75 and older. MR is a progressive disease that can lead to advanced stages of MR, heart failure, and other complications. Eyal Baror has been the CEO of the company since 2020. | Health Technology |
- Bolsa de valores
- Insiders
- Shlomo Noy